IT’S a biological stowaway that almost every adult on Earth carries, a silent passenger nestled within the very immune cells meant to protect us. For most, the Epstein-Barr virus (EBV) is a harmless squatter, a relic of a childhood fever or a teenage bout of glandular fever that settled into a lifelong slumber.
But for some, the passenger wakes up. And when it does, the consequences can be devastating, ranging from multiple sclerosis (MS) to Hodgkin’s lymphoma. Until now, tracking this invisible struggle between host and virus in healthy people was nearly impossible. We knew the virus was there, but we couldn’t see how hard the body was working to keep it quiet.
“Despite its high relevance, very little is known about how exactly the immune system controls lifelong EBV infection,” says Kerstin Ludwig at the University Hospital Bonn in Germany. The problem, she explains, has always been a lack of data. Measuring the “viral load”—the amount of virus actively circulating—requires specific, expensive laboratory tests that simply aren’t performed on hundreds of thousands of healthy people.
Now, Ludwig and her colleague Axel Schmidt have found a way to “repurpose” one of the largest hauls of biological data in history to unmask the virus’s hiding places. By combing through the genetic sequences of nearly 800,000 people from the UK Biobank and the US-based All of Us project, they have identified the genetic and lifestyle factors that determine who keeps the virus in check and who lets it slip the leash.
The breakthrough came from looking at what most geneticists consider “noise.” When researchers sequence a human genome, they aren’t just capturing human DNA; they are capturing bits of everything in that person’s blood at the time. “Genome sequencing data is actually collected to characterize the human genome—so we have ‘repurposed’ it a little,” says Schmidt.
By hunting for short snippets of DNA that matched the EBV genome rather than the human one, the team could estimate the viral load in each participant. They found these viral “reads” in about 16 to 22 per cent of the individuals studied. Those with the highest number of viral fragments weren’t just unlucky; they shared specific traits that suggested their immune systems were struggling.
One of the most striking findings was the link to smoking. We’ve long known that smoking is a risk factor for EBV-associated diseases, but the “why” remained a mystery. Schmidt’s data suggests a direct connection: “Our data indicate that current smoking in particular increases EBV viral load”. It seems that the chemical onslaught of a cigarette doesn’t just damage the lungs; it may hobble the innate immune system’s ability to keep EBV in its dormant state.
The team also noticed a seasonal rhythm to the virus. Samples taken in the winter months tended to have higher viral loads than those taken in the summer. It is a finding that hints at the subtle ways our environment—perhaps through vitamin D levels or the stress of winter infections—tips the scales in favor of the virus.
But the real treasure was buried in the DNA itself. The researchers identified 27 regions of the human genome, outside of the well-known immune system hubs, that appear to dictate EBV control. Some of these genes are already known to cause rare, severe immune deficiencies when they fail, but Schmidt and Ludwig found that common variations in these same genes can determine how well a “healthy” person manages their viral passenger.
This isn’t just a matter of academic curiosity. By comparing these genetic “control” regions with the DNA signatures of various diseases, the team found significant overlaps. They discovered that the same genetic variants that make it harder for the body to control EBV are also linked to an increased risk of multiple sclerosis and rheumatoid arthritis. In the case of MS, one specific immune-tagging gene called *HLA-A*02:01* stood out as a master regulator, helping the body maintain better control of the virus and, in turn, lowering disease risk.
Perhaps most surprisingly, the study pointed toward EBV playing a role in diseases where it was never previously suspected, such as type 1 diabetes.
“Our results serve as a basis for understanding EBV immunity,” says Ludwig. By turning the by-products of genomic research into a diagnostic tool, the team hasn’t just shed light on one virus. They’ve provided a blueprint for tracking other “silent” infections that may be sculpting our health from the shadows. For the 95 per cent of us carrying EBV, the passenger may still be there, but it is finally starting to lose its anonymity.
Study link: https://www.nature.com/articles/s41586-026-10274-4
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.